<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01643382</url>
  </required_header>
  <id_info>
    <org_study_id>HiRT 042918</org_study_id>
    <nct_id>NCT01643382</nct_id>
  </id_info>
  <brief_title>Hyperglycemia in Renal Transplantation</brief_title>
  <acronym>HiRT</acronym>
  <official_title>Randomized Study of the Impact of Peri-operative Glucose Control on Short Term Renal Allograft Function After Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on multiple prior studies, kidney transplant recipients with diabetes are at higher&#xD;
      risk for poor initial graft function after transplant. Our study is designed to determine if&#xD;
      tight blood sugar control around the time of kidney transplant will improve short term graft&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Population- Our study population will include all adult diabetic patients undergoing deceased&#xD;
      donor renal transplantation or living donor transplantation in which a swap requires&#xD;
      transportation and resulting cold storage time. This will ensure a reasonable incidence of&#xD;
      our primary outcome (poor short term graft function) and eliminate the potential risk of&#xD;
      treating non-diabetic patients with insulin infusions. Patients already enrolled in a drug&#xD;
      trial designed to study the impact of the drug on graft function will be excluded.&#xD;
&#xD;
      Study Design- This will be a randomized control trial. Recipients will be randomized to&#xD;
      either tight peri-operative glucose control or standard management.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      Randomization Protocol- In order to ensure that patients are equally distributed between&#xD;
      groups, we will use block randomization. Blocks of 4 patients will be created with the total&#xD;
      number of experimental versus control assignments being equal across blocks. Patients will&#xD;
      then be randomly assigned to a block.&#xD;
&#xD;
      Interventions- The study group will be treated with an insulin infusion to achieve tight&#xD;
      glycemic control (100-140mg/dL). Each study patient will be started on an insulin infusion&#xD;
      prior to their operation. This infusion will continue throughout the operation and for 24&#xD;
      hours after completion of the transplant. Glucose control will then be left to the discretion&#xD;
      of the primary team.&#xD;
&#xD;
      The control group will be treated with bolus insulin based on a standard insulin sliding&#xD;
      scale.&#xD;
&#xD;
      Outcomes&#xD;
&#xD;
      Aim 1-&#xD;
&#xD;
      Primary endpoint- Our primary endpoint will be poor initial graft function defined by the&#xD;
      occurrence of DGF (defined by a decrease in serum creatinine of &lt;10%/day for 3 consecutive&#xD;
      days after transplant) or slow graft function (serum creatinine &gt;3 mg/dL 5 days after&#xD;
      transplant without dialysis)&#xD;
&#xD;
      Secondary endpoint- Secondary endpoints will include wound infection, length of hospital&#xD;
      stay, 30 day mortality, hypoglycemic episodes(glucose &lt;70 mg/dL) and stroke.&#xD;
&#xD;
      Aim 2-&#xD;
&#xD;
      Primary endpoint- Our primary endpoints will be acute rejection at 90 days and graft&#xD;
      survival/renal function at 3months, 6months and then yearly.&#xD;
&#xD;
      Statistical Analysis- Data will be described as means with standard deviations or percentages&#xD;
      with ranges based on whether the data represent continuous or categorical variables. The&#xD;
      t-test and chi-squared test will be used to test hypotheses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Poor Graft Function After Kidney Transplant</measure>
    <time_frame>7 days after transplant</time_frame>
    <description>Our primary endpoint will be poor initial graft function defined by the occurrence of DGF (defined by a decrease in serum creatinine of &lt;10%/day for 3 consecutive days after transplant) or slow graft function (serum creatinine &gt;3 mg/dL 5 days after transplant without dialysis)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetes</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Tight glucose control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard glucose control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL</description>
    <arm_group_label>Tight glucose control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin, Asp(B28)-</intervention_name>
    <description>Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.</description>
    <arm_group_label>Standard glucose control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patients&#xD;
&#xD;
          -  diabetic&#xD;
&#xD;
          -  end stage renal disease undergoing cadaveric renal transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  enrolled in concurrent study to test impact of a drug on graft function after&#xD;
             transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin Parekh, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Department of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parekh J, Niemann CU, Dang K, Hirose R. Intraoperative hyperglycemia augments ischemia reperfusion injury in renal transplantation: a prospective study. J Transplant. 2011;2011:652458. doi: 10.1155/2011/652458. Epub 2011 Sep 4.</citation>
    <PMID>21904663</PMID>
  </reference>
  <reference>
    <citation>Parekh J, Bostrom A, Feng S. Diabetes mellitus: a risk factor for delayed graft function after deceased donor kidney transplantation. Am J Transplant. 2010 Feb;10(2):298-303. doi: 10.1111/j.1600-6143.2009.02936.x. Epub 2010 Jan 6.</citation>
    <PMID>20055796</PMID>
  </reference>
  <results_reference>
    <citation>Parekh J, Roll GR, Wisel S, Rushakoff RJ, Hirose R. Effect of moderately intense perioperative glucose control on renal allograft function: a pilot randomized controlled trial in renal transplantation. Clin Transplant. 2016 Oct;30(10):1242-1249. doi: 10.1111/ctr.12811. Epub 2016 Sep 24.</citation>
    <PMID>27423055</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2012</study_first_posted>
  <results_first_submitted>September 18, 2020</results_first_submitted>
  <results_first_submitted_qc>October 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2020</results_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>kidney transplant</keyword>
  <keyword>end stage renal disease</keyword>
  <keyword>delayed draft function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tight Glucose Control</title>
          <description>Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.&#xD;
Insulin: Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL</description>
        </group>
        <group group_id="P2">
          <title>Standard Glucose Control</title>
          <description>Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.&#xD;
Insulin, Asp(B28)-: Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tight Glucose Control</title>
          <description>Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.&#xD;
Insulin: Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL</description>
        </group>
        <group group_id="B2">
          <title>Standard Glucose Control</title>
          <description>Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.&#xD;
Insulin, Asp(B28)-: Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="9.1"/>
                    <measurement group_id="B2" value="60.7" spread="11"/>
                    <measurement group_id="B3" value="60.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration dialysis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" spread="2.6"/>
                    <measurement group_id="B2" value="5.7" spread="2.7"/>
                    <measurement group_id="B3" value="5.8" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.6" spread="11"/>
                    <measurement group_id="B2" value="21.1" spread="9.9"/>
                    <measurement group_id="B3" value="19.9" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C</title>
          <units>percent hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="1.2"/>
                    <measurement group_id="B2" value="6.7" spread="1"/>
                    <measurement group_id="B3" value="6.6" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative diabetic regimen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Poor Graft Function After Kidney Transplant</title>
        <description>Our primary endpoint will be poor initial graft function defined by the occurrence of DGF (defined by a decrease in serum creatinine of &lt;10%/day for 3 consecutive days after transplant) or slow graft function (serum creatinine &gt;3 mg/dL 5 days after transplant without dialysis)</description>
        <time_frame>7 days after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tight Glucose Control</title>
            <description>Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.&#xD;
Insulin: Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL</description>
          </group>
          <group group_id="O2">
            <title>Standard Glucose Control</title>
            <description>Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.&#xD;
Insulin, Asp(B28)-: Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Poor Graft Function After Kidney Transplant</title>
          <description>Our primary endpoint will be poor initial graft function defined by the occurrence of DGF (defined by a decrease in serum creatinine of &lt;10%/day for 3 consecutive days after transplant) or slow graft function (serum creatinine &gt;3 mg/dL 5 days after transplant without dialysis)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tight Glucose Control</title>
          <description>Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.&#xD;
Insulin: Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL</description>
        </group>
        <group group_id="E2">
          <title>Standard Glucose Control</title>
          <description>Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.&#xD;
Insulin, Asp(B28)-: Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Justin Parekh, MD, MAS</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-595-3707</phone>
      <email>justin.parekh@ucsfmedctr.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

